The multinational blood products Grifols has today announced changes to its management team to “simplify the corporate governance of the company in order to guarantee the focus on obtaining results,” the company said in a statement. With this objective, the Board of Directors has appointed Thomas Glanzmann as CEO, who will also continue to hold the position of Executive Chairman.
For their part, the until now CEOs VÃctor Grifols Deu and Raimon Grifols, current vice president, will debut new functions at the multinational’s leadership. The first will become the director of operations, focusing on the day-to-day management of the company; while the latter will assume the position of corporate general manager, “focusing on optimizing the value of Grifols’ subsidiaries and corporate associations, as well as leading the main corporate initiatives,” the company has detailed.
The company hopes that the changes introduced will help it speed up the execution of its strategic plan and deepen the restructuring process started with the creation of business units. Last February, Grifols announced a comprehensive operational improvement plan promoting measures to increase its competitiveness, reduce its cost base, and improve its organizational efficiency and effectiveness.
Subsequently, in October of last year, it established the figure of the executive president to centralize the most strategic decision-making “in the face of a complex and changing environment”, separating the founding family from the first line of management for the first time. For the position, Steven F. Mayer was chosen, who resigned a few months later due to health and other personal reasons. In February he was replaced in office by Glanzmann. “I am sure that these changes will position us for our next stage of growth and will help us achieve results and accelerate our performance to meet our commitments to all of our stakeholders,” said the Chairman and new CEO of Grifols.
The multinational blood products recorded a profit of 208 million euros in 2022, 10.4% more than the previous year but a lower figure than that registered before the pandemic -618 million- due to the increase in the cost of donations plasma. However, revenue reached a record figure of 6,064 million euros, 12.4% more than in 2021.
